| Important
messages for client |
| • |
Dogs
with primary epilepsy are normal animals with lower seizure
threshold. |
| • |
The
aim of anticonvulsant treatment is not to cure epilepsy but
to “control” it. |
| • |
Side-effects
of anticonvulsant treatments are occasionally
worse than the
seizures themselves. |
| • |
Mild
side-effects are common when first starting
treatment with
anticonvulsant drug. |
| • |
Therapeutic
effects and side-effects are related to
serum level and not
oral dosage of the anti-epileptic drug. |
| • |
Oral
anticonvulsant drugs may take a long time to be
effective,
so seizure control may not be immediate. |
| • |
Client
must keep accurate record of witnessed or suspected seizures. |
| • |
Client
must be willing to bring their dog or cat in for periodic examination. |
| • |
Client
should seek immediate veterinary care for any seizure lasting
longer
than 10 minutes or for clusters of seizures without recovery
between. |
| • |
Client
should not alter the treatment without veterinary advice. |
| • |
Skipping
doses or stopping drugs abruptly can precipitate seizures. |
Phenobarbitone
Therapeutic and toxic effects of phenobarbitone are related to serum concentrations
and not the quantity of drug administered orally. Therapeutic monitoring
of serum phenobarbitone concentration can be helpful in determining the
optimal dose. |
| |
|
| Monitoring
should be performed: |
| • |
When
steady state blood levels are reached after starting treatment
or after changing oral dosage (12 to 15 days in dogs). This
provides a baseline to guide further changes in doses according
to clinical circumstances. |
| • |
If
seizure frequency increases. |
| • |
Every
3 to 6 months to verify that blood concentrations are maintained
in the therapeutic range. |
| • |
If
drug-related side-effects are suspected. |
| • |
If
drugs are added that might interfere with phenobarbitone’s
pharmacokinetics
(corticosteroids, cimetidine, chloramphenicol). |
| |
Recommended
therapeutic range in dogs is 20 to 35 ug/ml (65-194µmol/l).
Most dogs will “respond” (reduction in frequency,
intensity and severity of the seizures with minimal side-effects)
when the serum level of phenobarbitone is within this range.
However, some dogs might need to be in the upper limit of this
range while others might need to be below the lower limit.
This
therapeutic range is only an indication of changes required in
the oral dosage. |
| |
|
| Monitoring
of serum bromide concentration should be performed: |
| • |
When
steady state blood levels are reached after starting treatment
or after changing oral dosage (3 to 6 months in dogs). This
provides a baseline to guide further changes in doses according
to clinical circumstances. |
| • |
If
seizure frequency increases. |
| • |
Every
6 to 12 months to verify that blood concentrations
are maintained
in the therapeutic range. |
| • |
If
drug-related side effects are suspected. |
| |
|
| Recommended
oral dosage in dogs is 30 mg/kg once daily. Therapeutic serum concentrations
are 880 to 3000 mg/ml as a solitary agent and 810 to 2400 mg/ml
in combination with phenobarbitone. |